MDS (Myelodysplastic Syndrome) clinical trials
Showing 201–250 of 284 active trials. Describe your situation to see which ones you may be eligible for.
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
- Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
- A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
- Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
- The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
- A Phase 1-3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)
- Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients
- Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes
- Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
- Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
- Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
- Caris Chromoseq Data Collection
- Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
- A Long Term Follow-up Study of TScan TCR-T Products
- The International PNH Interest Group PNH Registry
- Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy
- CHIP/CCUS Natural History Protocol
- Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
- Collection of Tissue Samples for Cancer Research
- Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
- HPC Offered for PRESERVE Expansion
- Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
- Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
- Activity Levels in Bone Marrow Transplant Patients
- Umbilical Cord Blood Transplantation From Unrelated Donors
- Familial Investigations of Childhood Cancer Predisposition
- Investigation of the Genetics of Hematologic Diseases
- Cancer Experience Registry (CER) for Cancer Patients and Caregivers
- Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- Natural History Study of GATA2 Deficiency and Related Disorders
- The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Registry of Older Patients With Cancer
- Home Blood Transfusions
- Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories
- The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
- A Telehealth Advance Care Planning Intervention
- HEME Home Transfusion Program
- eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation
- GM-CSF With Post-Transplant Cyclophosphamide
- TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
- Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
- Mosaic Trial for Stem Cell Transplant Recipients
- Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients
- Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.